Form D · Pharmaceuticals
INNOVUS PHARMACEUTICALS, INC.
San Diego, CA · CIK 0001411879
Offering snapshot reported Jan 11, 2019 · SEC filing
- Reported sold
- $3.17M Offering amount: $3.17M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 3, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 11, 2019 | Initial | $3,171,445 | No comparison | 1 | SEC filing |
| Aug 2, 2017 | Initial | $145,200 | No comparison | 1 | SEC filing |
| Aug 2, 2016 | Initial | $3,000,000 | No comparison | 9 | SEC filing |
| Aug 6, 2015 | Initial | $16,000 | No comparison | 0 | SEC filing |
| Aug 6, 2015 | Initial | $500,000 | No comparison | 0 | SEC filing |
| Feb 25, 2014 | Initial | $330,000 | No comparison | 1 | SEC filing |
| Feb 25, 2014 | Initial | $742,300 | No comparison | 6 | SEC filing |
| Jan 7, 2014 | Initial | $350,000 | No comparison | 1 | SEC filing |
| Jan 7, 2014 | Initial | $0 | No comparison | 28 | SEC filing |
| Aug 28, 2013 | Initial | $1,070,000 | No comparison | 2 | SEC filing |
| Aug 28, 2013 | Initial | $50,000 | No comparison | 1 | SEC filing |
| Aug 28, 2013 | Initial | $174,668 | No comparison | 6 | SEC filing |
| Aug 28, 2013 | Initial | $50,000 | No comparison | 1 | SEC filing |
| Aug 28, 2013 | Amendment | $50,000 | $0vs Aug 28, 2013 | 1 | SEC filing |
| Aug 26, 2013 | Initial | $134,640 | No comparison | 2 | SEC filing |
| Aug 26, 2013 | Initial | $4,484,661 | No comparison | 6 | SEC filing |
| May 20, 2013 | Initial | $450,000 | No comparison | 1 | SEC filing |
| May 30, 2012 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Mar 23, 2012 | Initial | $0 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $355K
- Finders' fees
- $0
- Form D file number
- 021-330234
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. WAINWRIGHT and CO., LLC | 375 |
Source: Form D, filed Jan 11, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Randy Berholtz | Executive |
| Wallace Boyack | Director, Executive |
| Morgan Reed Brown | Executive |
| Bassam Damaj | Director, Executive |
| Henry Esber | Director |
| Vivian Liu | Director |
| Ziad Mirza | Director |
| Dean Nuhaily | Director |
| Ryan Selhorn | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
8845 Rehco Road
San Diego, CA, 92121
San Diego, CA, 92121